Results 41 to 50 of about 19,211 (198)

CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes andphenytoin adverse reactions correlation

Arquivos de Neuro-Psiquiatria, 2011
OBJECTIVE: CYP2C9 is a major enzyme in human drug metabolism and the polymorphism observed in the corresponding gene may affect therapeutic outcome during treatment. The distribution of variant CYP2C9 alleles and prevalence of phenytoin adverse reactions
Carlos Alexandre Twardowschy, Lineu César Werneck, Rosana Herminia Scola, Luciano De Paola, Carlos Eduardo Silvado   +4 more
doaj   +1 more source

Identification and in vitro functional assessment of 10 CYP2C9 variants found in Chinese Han subjects

Frontiers in Endocrinology, 2023
Cytochrome P450 2C9 (CYP2C9) participates in about 15% of clinical drug metabolism, and its polymorphism is associated with individual drug metabolism differences, which may lead to the adverse drug reactions (ADRs).
Qing Zhang, Qing Zhang, Qing Zhang, Yuying Qi, Yuying Qi, Shuanghu Wang, Fangling Zhao, Fangling Zhao, Lili Zou, Lili Zou, Lili Zou, Quan Zhou, Peiwu Geng, Yun Hong, Yun Hong, Hang Yang, Hang Yang, Qingfeng Luo, Qingfeng Luo, Jianping Cai, Hualan Wu, Hualan Wu, Dongxu Wang, Dongxu Wang, Hao Chen, Hao Chen, Jiefu Yang, Jiefu Yang, Jiefu Yang, Dapeng Dai   +29 more
doaj   +1 more source

CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations

Pharmacogenomics and Personalized Medicine, 2021
Sheikh Nizamuddin,1,2 Shivendra Dubey,1 Sakshi Singh,1 Saurav Sharma1 ,† Pratheusa Machha,1,3 Kumarasamy Thangaraj1,3,4 1CSIR-Centre for Cellular and Molecular Biology, Hyderabad 500007, India; 2German Cancer Consortium (DKTK) c/o Zentrale ...
Nizamuddin S, Dubey S, Singh S, Sharma S, Machha P, Thangaraj K   +5 more
doaj  

Precision medicine in paediatrics: Progress and priorities

British Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain, Claire Booth, Joseph F. Standing, Charlotte I. S. Barker   +3 more
wiley   +1 more source

Assessment of susceptibility to phthalate and DINCH exposure through CYP and UGT single nucleotide polymorphisms

Environment International, 2022
Single nucleotide polymorphisms (SNPs) of cytochrome P450 (CYPs) and UDP-glucuronosyltransferase (UGTs) genes have been proposed to influence phthalates and 1,2-cyclo-hexanedicarboxylic acid diisononyl ester (DINCH) biotransformation but have not been ...
Anja Stajnko, Agneta Annika Runkel, Tina Kosjek, Janja Snoj Tratnik, Darja Mazej, Ingrid Falnoga, Milena Horvat   +6 more
doaj   +1 more source

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source

CYP2C9*2 and CYP2C9*3 allele variants of CYP2C9 cytochrome gene in St. Petersburg population, and their clinical role in warfarin anticoagulant therapy

Российский кардиологический журнал, 2004
One of the leading anticoagulants in Russia is warfarin. Its pharmacokinetics is determined by structural polymorphisms of CYP2C9 cytochrome gene, metabolizing warfarin.
O. V. Sirotkina, A. S. Ulitina, A. E. Taraskina, M. I. Kadinskaya, T. V. Vavilova, S. N. Pchelina, E. I. Shwartz   +6 more
doaj  

Characterization of Lysosomal Hydrolases and Transporters and Their Age‐Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Lysosomes play a key role in the accumulation, catabolism, and transport of endogenous and exogenous metabolites and proteins and are involved in drug metabolism and prodrug activation. However, the protein abundance and interindividual variability of lysosomal drug‐metabolizing enzymes and transporters (DMETs) remain underexplored.
Darshak Gadara, Dilip Kumar Singh, Sandhya Subash, Guihua Yue, Deepak Ahire, Chris Bohl, Maciej Czerwinski, Stephanie Helmstetter, Scott Heyward, Robert S. Jones, Cyrus Khojasteh, Ryota Kikuchi, Priyanka Kulkarni, Bin Ma, Bernard Murray, Chris Seib, Bill Smith, David M. Stresser, Mitchell E. Taub, Ting Wang, Bhagwat Prasad   +20 more
wiley   +1 more source

CYP2C8 and CYP2C9 mRNA expression profile in the human fetus

Frontiers in Genetics, 2014
CYP2C8 and CYP2C9 are involved in the inactivation of several NSAIDs, including ibuprofen. CYP2C9 is the major form in human liver whereas CYP2C8 has been proposed to be the main CYP2C enzyme in fetal liver.
Maria eJohansson, Emmanuel eStrahm, Anders eRane, Lena eEkström   +3 more
doaj   +1 more source

Virtual Twin Approach Using Physiologically Based Pharmacokinetic Modeling to Support Precision Dosing of Valproic Acid in Geriatric Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Personalized dosing is particularly important for drugs with narrow therapeutic indices in geriatric patients, who exhibit substantial physiological variability and limited pharmacokinetic (PK) evidence to guide individualized dose selection. Valproic acid (VPA) is an effective treatment option for bipolar disorder in older adults, yet dosing largely ...
Yoo Jin Jang, Dong‐Gyu Heo, Eunjin Hong   +2 more
wiley   +1 more source